What are the key takeaways from this Beyond Biotech episode?

Key insights include: **Mechanism differentiation:** GPX002 delivers two genes — PDX1 and MAFA — that transdifferentiate alpha cells into insulin-producing beta cells. For type one, this creates entirely new beta cell mass where none exists. For type two, it restores exhausted beta cells' ability to produce insulin effectively, even when a high-fat diet continues inducing hyperglycemia.; **GLP-1 blind spot:** GLP-1 drugs do not address type one diabetes at all, since the condition involves the immune system destroying beta cells — a process GLP-1s cannot counteract. Even in type two, GLP-1s only reduce insulin demand rather than repair depleted beta cells, leaving a structural treatment gap that gene therapy targets.; **Durability advantage over stem cells:** In type one animal models, GPX002 normalized glucose levels for 15–16 weeks post-treatment. Stem cell-based approaches from competitors show beta cells destroyed by immune response within 16–18 days. This duration gap is Genprex's primary competitive argument for gene therapy over stem cell platforms from Vertex and others.

What did Genprex Bets discuss on Beyond Biotech?

Genprex CEO Ryan Comfer explains how GPX002, a gene therapy using PDX1 and MAFA genes delivered via AAV vector, aims to restore pancreatic beta cell function in both type one and type two diabetes — positioning it as a potential one-time functional cure alongside, not against, GLP-1 drugs. Key topics include: **Mechanism differentiation:** GPX002 delivers two genes — PDX1 and MAFA — that transdifferentiate alpha cells into insulin-producing beta cells. For type one, this creates entirely new beta cell mass where none exists. For type two, it restores exhausted beta cells' ability to produce insulin effectively, even when a high-fat diet continues inducing hyperglycemia.; **GLP-1 blind spot:** GLP-1 drugs do not address type one diabetes at all, since the condition involves the immune system destroying beta cells — a process GLP-1s cannot counteract. Even in type two, GLP-1s only reduce insulin demand rather than repair depleted beta cells, leaving a structural treatment gap that gene therapy targets..

How long is this episode of Beyond Biotech?

This episode is 34 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Beyond Biotech

Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)

October 30, 2026

34 min episode · 2 min read

Genprex Bets

Episode

34 min

Read time

2 min

Topics

Relationships, Startups, Leadership

AI-Generated Summary

Published Oct 30, 2026

Key Takeaways

✓Mechanism differentiation: GPX002 delivers two genes — PDX1 and MAFA — that transdifferentiate alpha cells into insulin-producing beta cells. For type one, this creates entirely new beta cell mass where none exists. For type two, it restores exhausted beta cells' ability to produce insulin effectively, even when a high-fat diet continues inducing hyperglycemia.
✓GLP-1 blind spot: GLP-1 drugs do not address type one diabetes at all, since the condition involves the immune system destroying beta cells — a process GLP-1s cannot counteract. Even in type two, GLP-1s only reduce insulin demand rather than repair depleted beta cells, leaving a structural treatment gap that gene therapy targets.
✓Durability advantage over stem cells: In type one animal models, GPX002 normalized glucose levels for 15–16 weeks post-treatment. Stem cell-based approaches from competitors show beta cells destroyed by immune response within 16–18 days. This duration gap is Genprex's primary competitive argument for gene therapy over stem cell platforms from Vertex and others.
✓LNP as next-generation delivery: Genprex is developing lipid nanoparticle delivery as a version 2.0 alongside AAV. LNPs allow redosing — a critical advantage in type one where immune response can degrade AAV-delivered therapy over time. Genprex claims to be the first to successfully deliver gene therapy via LNP directly into pancreatic islets.
✓Lean university partnership model: Genprex outsources nearly all diabetes R&D to University of Pittsburgh under a licensing deal that funds Dr. Giddes' lab to continue research. This eliminates the need for internal lab infrastructure, allowing a small team to run parallel oncology and diabetes programs while retaining strategic control and transferring constructs when ready for CDMO scaling.

What It Covers

Genprex CEO Ryan Comfer explains how GPX002, a gene therapy using PDX1 and MAFA genes delivered via AAV vector, aims to restore pancreatic beta cell function in both type one and type two diabetes — positioning it as a potential one-time functional cure alongside, not against, GLP-1 drugs.

Key Questions Answered

•Mechanism differentiation: GPX002 delivers two genes — PDX1 and MAFA — that transdifferentiate alpha cells into insulin-producing beta cells. For type one, this creates entirely new beta cell mass where none exists. For type two, it restores exhausted beta cells' ability to produce insulin effectively, even when a high-fat diet continues inducing hyperglycemia.
•GLP-1 blind spot: GLP-1 drugs do not address type one diabetes at all, since the condition involves the immune system destroying beta cells — a process GLP-1s cannot counteract. Even in type two, GLP-1s only reduce insulin demand rather than repair depleted beta cells, leaving a structural treatment gap that gene therapy targets.
•Durability advantage over stem cells: In type one animal models, GPX002 normalized glucose levels for 15–16 weeks post-treatment. Stem cell-based approaches from competitors show beta cells destroyed by immune response within 16–18 days. This duration gap is Genprex's primary competitive argument for gene therapy over stem cell platforms from Vertex and others.
•LNP as next-generation delivery: Genprex is developing lipid nanoparticle delivery as a version 2.0 alongside AAV. LNPs allow redosing — a critical advantage in type one where immune response can degrade AAV-delivered therapy over time. Genprex claims to be the first to successfully deliver gene therapy via LNP directly into pancreatic islets.
•Lean university partnership model: Genprex outsources nearly all diabetes R&D to University of Pittsburgh under a licensing deal that funds Dr. Giddes' lab to continue research. This eliminates the need for internal lab infrastructure, allowing a small team to run parallel oncology and diabetes programs while retaining strategic control and transferring constructs when ready for CDMO scaling.

Notable Moment

Comfer describes inducing complete beta cell destruction in animal models — requiring insulin just to keep them alive — then administering GPX002 and watching insulin requirements drop immediately, with glucose levels staying normalized for 15–16 weeks, a result he contrasts sharply with stem cell approaches lasting only days.

Know someone who'd find this useful?

Episode Transcript

Welcome to Beyond Biotech and this third and final part of our series on GLP-1s and the future of metabolic health. A series we're calling The Metabolic Moment. In just a few years, GLP-1s have become a phenomenon. They've transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting, cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure. So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we'll follow the money, the science, and the people behind this metabolic moment. GLP-one drugs have changed how we treat type two diabetes. But they manage the disease, rather than repair what's broken. Genprex, a gene therapy company based in Austin, Texas, is taking a different approach. Its candidate, GPX002, uses an AAV vector to deliver two genes directly to the pancreas to restore beta cell function in both type one and type two diabetes. Earlier this year, the company presented preclinical data at ASGCT showing the therapy reversed high blood sugar in mouse models of type two diabetes. Now Genprex is preparing for IND enabling studies and has signed a manufacturing partner to help scale it up. Ahead of Diabetes Awareness Month, I spoke with Ryan Comfer, President and CEO of Genprex, about the company's move from cancer into diabetes, the reality of making gene therapies at scale, and where a potential one time treatment could fit alongside GLP-one's. Ryan, welcome to Beyond Biotech. Thank you. Great to meet you. Ryan, you've been with Genprex since 2011, and you've been the president and CEO since 2024. How did you actually come to lead Genprex? What drew you to gene therapy in the first place? Yeah, so my background was in early stage technology investments, and got involved in the kind of entrepreneurial startup community in Austin, Texas about twenty years ago, and happened to know the former CEO of a publicly traded biotech at the time. And one of his scientific advisors for their company was a researcher at MD Anderson, Doctor. Jack Roth. And so I came to know Doctor. Roth quite well, and it was the culmination of his research at MD Anderson. He was a practicing thoracic surgeon and oncologist specifically treating lung cancer. And so he had spent his entire career researching lung cancer. And so this was the culmination of his research efforts. He has over a thousand publications to his name, and is just recognized as a leader in the space. And so this project was his baby. And so I've known about it for some time, and myself and a few others had the opportunity to license that technology out of MD Anderson back in 2009. At the time, I was involved in a number of other startup projects …

Get the full transcript (5,170 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Beyond Biotech transcripts →